1. Home
  2. SLNO vs AMRX Comparison

SLNO vs AMRX Comparison

Compare SLNO & AMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLNO
  • AMRX
  • Stock Information
  • Founded
  • SLNO 1999
  • AMRX 2002
  • Country
  • SLNO United States
  • AMRX United States
  • Employees
  • SLNO N/A
  • AMRX N/A
  • Industry
  • SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • AMRX Biotechnology: Pharmaceutical Preparations
  • Sector
  • SLNO Health Care
  • AMRX Health Care
  • Exchange
  • SLNO Nasdaq
  • AMRX Nasdaq
  • Market Cap
  • SLNO 3.8B
  • AMRX 3.3B
  • IPO Year
  • SLNO 2014
  • AMRX N/A
  • Fundamental
  • Price
  • SLNO $65.46
  • AMRX $9.91
  • Analyst Decision
  • SLNO Strong Buy
  • AMRX Buy
  • Analyst Count
  • SLNO 9
  • AMRX 3
  • Target Price
  • SLNO $116.78
  • AMRX $12.00
  • AVG Volume (30 Days)
  • SLNO 1.7M
  • AMRX 1.6M
  • Earning Date
  • SLNO 11-05-2025
  • AMRX 10-30-2025
  • Dividend Yield
  • SLNO N/A
  • AMRX N/A
  • EPS Growth
  • SLNO N/A
  • AMRX N/A
  • EPS
  • SLNO N/A
  • AMRX 0.01
  • Revenue
  • SLNO $32,656,999.00
  • AMRX $2,852,914,000.00
  • Revenue This Year
  • SLNO N/A
  • AMRX $9.52
  • Revenue Next Year
  • SLNO $182.29
  • AMRX $6.31
  • P/E Ratio
  • SLNO N/A
  • AMRX $923.16
  • Revenue Growth
  • SLNO N/A
  • AMRX 9.81
  • 52 Week Low
  • SLNO $41.50
  • AMRX $6.69
  • 52 Week High
  • SLNO $90.32
  • AMRX $10.68
  • Technical
  • Relative Strength Index (RSI)
  • SLNO 51.66
  • AMRX 49.88
  • Support Level
  • SLNO $63.02
  • AMRX $9.56
  • Resistance Level
  • SLNO $72.88
  • AMRX $9.98
  • Average True Range (ATR)
  • SLNO 4.25
  • AMRX 0.29
  • MACD
  • SLNO 1.03
  • AMRX -0.08
  • Stochastic Oscillator
  • SLNO 56.61
  • AMRX 30.63

About SLNO Soleno Therapeutics Inc.

Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.

About AMRX Amneal Pharmaceuticals Inc.

Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE - It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.

Share on Social Networks: